iams3by personal page - To The Moon

iams3by

No personal profile

0Follow

1Followers

0Topic

0Badge

2022-02-04

Buy the dip

Sorry, the original content has been removed

2022-01-14

It will climb back soon. Just have to be patience 😎

Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%

2022-01-13

Time to buy more

Sorry, the original content has been removed

2022-01-13

$Pfizer(PFE)$Slowly but surely 😎

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4104687611168670,"uuid":"4104687611168670","gmtCreate":1641584542654,"gmtModify":1641584542654,"name":"iams3by","pinyin":"iams3by","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.05.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9091775572,"gmtCreate":1643953549673,"gmtModify":1676533875952,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy the dip","listText":"Buy the dip","text":"Buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091775572","repostId":"1180306841","repostType":4,"isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005970252,"gmtCreate":1642160840864,"gmtModify":1676533687588,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It will climb back soon. Just have to be patience 😎","listText":"It will climb back soon. Just have to be patience 😎","text":"It will climb back soon. Just have to be patience 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005970252","repostId":"1141205139","repostType":2,"repost":{"id":"1141205139","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642158579,"share":"https://www.laohu8.com/m/news/1141205139?lang=&edition=full","pubTime":"2022-01-14 19:09","market":"us","language":"en","title":"Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141205139","media":"Tiger Newspress","summary":"Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.Moderna, BioNtech and Pfize","content":"<html><head></head><body><p>Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.</p><p>Moderna, BioNtech and Pfizer fell between 1% and 4%.<img src=\"https://static.tigerbbs.com/41f83c9f798e54250bcb5d6639f341d9\" tg-width=\"717\" tg-height=\"605\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks tumbled in premarket trading. Novavax shares fell over 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-14 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.</p><p>Moderna, BioNtech and Pfizer fell between 1% and 4%.<img src=\"https://static.tigerbbs.com/41f83c9f798e54250bcb5d6639f341d9\" tg-width=\"717\" tg-height=\"605\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141205139","content_text":"Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.Moderna, BioNtech and Pfizer fell between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002210808,"gmtCreate":1642027149507,"gmtModify":1676533672032,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to buy more","listText":"Time to buy more","text":"Time to buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002210808","repostId":"1117693983","repostType":2,"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002674413,"gmtCreate":1642008516633,"gmtModify":1676533671232,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>Slowly but surely 😎","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>Slowly but surely 😎","text":"$Pfizer(PFE)$Slowly but surely 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002674413","isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9005970252,"gmtCreate":1642160840864,"gmtModify":1676533687588,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"It will climb back soon. Just have to be patience 😎","listText":"It will climb back soon. Just have to be patience 😎","text":"It will climb back soon. Just have to be patience 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005970252","repostId":"1141205139","repostType":2,"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002674413,"gmtCreate":1642008516633,"gmtModify":1676533671232,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>Slowly but surely 😎","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>Slowly but surely 😎","text":"$Pfizer(PFE)$Slowly but surely 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002674413","isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091775572,"gmtCreate":1643953549673,"gmtModify":1676533875952,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Buy the dip","listText":"Buy the dip","text":"Buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091775572","repostId":"1180306841","repostType":4,"repost":{"id":"1180306841","pubTimestamp":1643946520,"share":"https://www.laohu8.com/m/news/1180306841?lang=&edition=full","pubTime":"2022-02-04 11:48","market":"us","language":"en","title":"2 Big Reasons to Buy the Dip in Meta Platforms' Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1180306841","media":"Motley Fool","summary":"Key PointsThe metaverse could be a $1.6 trillion opportunity by 2030.The opportunity dwarfs the cash","content":"<html><head></head><body><p>Key Points</p><ul><li>The metaverse could be a $1.6 trillion opportunity by 2030.</li><li>The opportunity dwarfs the cash that Meta&#39;s Reality Labs segment is burning trying to build it.</li></ul><p><a href=\"https://laohu8.com/S/FB\"><b>Meta Platforms</b></a>, the parent company of popular social media apps Facebook, Instagram, and WhatsApp, reported its full-year 2021 earnings on Feb. 2. Investors were not at all happy about the significant cash burn in the company&#39;s Reality Labs segment, which is focused on building the metaverse, and in the weaker-than-expected forward guidance.</p><p>Meta&#39;s stock price fell 22% in after-hours trading following the report&#39;s release (and has stayed down), but there are strong arguments in support of investors buying into that weakness. The company&#39;s impeccable track record of financial performance suggests it deserves the benefit of the doubt, especially given the opportunities ahead.</p><p>Here are two key reasons to buy this dip.</p><p><b>1. The huge potential of the metaverse is worth the billions being invested</b></p><p>Meta Platforms is the largest social media company in the world, with its Facebook asset alone used by 2.91 billion people every month -- a startling 36% of the entire global population. But still, the company refuses to slip into complacency, as evidenced by its sizeable (and increasing) investment in the metaverse.</p><p>This new virtual world is being constructed by Meta&#39;s Reality Labs segment, which the company now reports separately from the rest of its platforms. It believes that in the future, its users will exist as virtual avatars of themselves within the metaverse, where they can teleport to different experiences and carry inventories of digital goods. That presents a significant financial opportunity for Meta Platforms, because the metaverse could feature its own self-sustaining economy.</p><p>But when the company revealed its fourth-quarter 2021 result, investors were surprised at just how much money was being spent on this project.</p><p><img src=\"https://static.tigerbbs.com/c8a56d3077c1ad468aa5b988b90d0a6d\" tg-width=\"1065\" tg-height=\"156\" referrerpolicy=\"no-referrer\"/>While it appears the Reality Labs segment is bleeding an increasing amount of red ink, Meta Platforms is playing the long game. One estimate by Bloomberg Intelligence suggests themetaversewill be an $800 billion opportunity by 2024, with a 12.4% compound annual growth rate (CAGR) that could see it double to $1.6 trillion by the end of this decade alone. Therefore, in context, the $10.1 billion Reality Labs lost during 2021 could be a mere drop in the ocean compared to its future revenue potential.</p><p><b>2. The stock is a great value</b></p><p>Despite Meta&#39;s substantial commitment to building the metaverse, the company as a whole is making a significant amount of money. For the 2021 full year, it reported $39.3 billion in operating income, which translated into $13.77 inearnings per share.</p><p>Its stock trades at $239 right now, placing itsprice-to-earnings multipleat just 17.1. That&#39;s 50% cheaper than the technology-centric <b>Nasdaq-100</b> index, which trades at a multiple of 33.7. Meta has a stellar track record of revenue and earnings growth over the last decade, which likely warrants a much richer stock valuation.</p><p><img src=\"https://static.tigerbbs.com/6afeeff414d72fdbfaee8fe2d9fe409f\" tg-width=\"1066\" tg-height=\"235\" referrerpolicy=\"no-referrer\"/>But putting the past aside, the short term might be bumpy as Meta contends with recent changes to user privacy policies for<b>Apple</b>&#39;s iOS and<b>Alphabet</b>&#39;s Google Andriod OS, which are making it harder for advertisers to accurately target their desired audiences. That, combined with lingering supply chain issues hurting businesses&#39; appetite to spend on marketing, prompted Meta to issue conservative guidance for the first quarter of 2022.</p><p>There is another concern. Facebook saw its first sequential quarterly decline in daily active users in company history, and although it was a mere 0.05% contraction in user base, it highlights the difficulty in generating growth for a single platform with over 1.9 billion users. But on the plus side, Meta recorded an average revenue per user of $9.39 for the fourth quarter, its highest in at least two years.</p><p><b>Investor takeaway</b></p><p>Meta is an incredibly innovative company, so issues like ad targeting and short-term supply chain issues will likely be overcome given enough time. It favors a long-term investment approach, especially given the opportunity in the metaverse that lies ahead. If the new virtual world grows as large as some estimates suggest, the company&#39;s future financial performance could trounce anything it has achieved in the past. Therefore, picking up Meta Platforms stock on this dip could be a game-changer for your portfolio.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Big Reasons to Buy the Dip in Meta Platforms' Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Big Reasons to Buy the Dip in Meta Platforms' Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-04 11:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/03/2-big-reasons-buy-the-dip-in-meta-platforms-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key PointsThe metaverse could be a $1.6 trillion opportunity by 2030.The opportunity dwarfs the cash that Meta's Reality Labs segment is burning trying to build it.Meta Platforms, the parent company ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/03/2-big-reasons-buy-the-dip-in-meta-platforms-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2022/02/03/2-big-reasons-buy-the-dip-in-meta-platforms-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180306841","content_text":"Key PointsThe metaverse could be a $1.6 trillion opportunity by 2030.The opportunity dwarfs the cash that Meta's Reality Labs segment is burning trying to build it.Meta Platforms, the parent company of popular social media apps Facebook, Instagram, and WhatsApp, reported its full-year 2021 earnings on Feb. 2. Investors were not at all happy about the significant cash burn in the company's Reality Labs segment, which is focused on building the metaverse, and in the weaker-than-expected forward guidance.Meta's stock price fell 22% in after-hours trading following the report's release (and has stayed down), but there are strong arguments in support of investors buying into that weakness. The company's impeccable track record of financial performance suggests it deserves the benefit of the doubt, especially given the opportunities ahead.Here are two key reasons to buy this dip.1. The huge potential of the metaverse is worth the billions being investedMeta Platforms is the largest social media company in the world, with its Facebook asset alone used by 2.91 billion people every month -- a startling 36% of the entire global population. But still, the company refuses to slip into complacency, as evidenced by its sizeable (and increasing) investment in the metaverse.This new virtual world is being constructed by Meta's Reality Labs segment, which the company now reports separately from the rest of its platforms. It believes that in the future, its users will exist as virtual avatars of themselves within the metaverse, where they can teleport to different experiences and carry inventories of digital goods. That presents a significant financial opportunity for Meta Platforms, because the metaverse could feature its own self-sustaining economy.But when the company revealed its fourth-quarter 2021 result, investors were surprised at just how much money was being spent on this project.While it appears the Reality Labs segment is bleeding an increasing amount of red ink, Meta Platforms is playing the long game. One estimate by Bloomberg Intelligence suggests themetaversewill be an $800 billion opportunity by 2024, with a 12.4% compound annual growth rate (CAGR) that could see it double to $1.6 trillion by the end of this decade alone. Therefore, in context, the $10.1 billion Reality Labs lost during 2021 could be a mere drop in the ocean compared to its future revenue potential.2. The stock is a great valueDespite Meta's substantial commitment to building the metaverse, the company as a whole is making a significant amount of money. For the 2021 full year, it reported $39.3 billion in operating income, which translated into $13.77 inearnings per share.Its stock trades at $239 right now, placing itsprice-to-earnings multipleat just 17.1. That's 50% cheaper than the technology-centric Nasdaq-100 index, which trades at a multiple of 33.7. Meta has a stellar track record of revenue and earnings growth over the last decade, which likely warrants a much richer stock valuation.But putting the past aside, the short term might be bumpy as Meta contends with recent changes to user privacy policies forApple's iOS andAlphabet's Google Andriod OS, which are making it harder for advertisers to accurately target their desired audiences. That, combined with lingering supply chain issues hurting businesses' appetite to spend on marketing, prompted Meta to issue conservative guidance for the first quarter of 2022.There is another concern. Facebook saw its first sequential quarterly decline in daily active users in company history, and although it was a mere 0.05% contraction in user base, it highlights the difficulty in generating growth for a single platform with over 1.9 billion users. But on the plus side, Meta recorded an average revenue per user of $9.39 for the fourth quarter, its highest in at least two years.Investor takeawayMeta is an incredibly innovative company, so issues like ad targeting and short-term supply chain issues will likely be overcome given enough time. It favors a long-term investment approach, especially given the opportunity in the metaverse that lies ahead. If the new virtual world grows as large as some estimates suggest, the company's future financial performance could trounce anything it has achieved in the past. Therefore, picking up Meta Platforms stock on this dip could be a game-changer for your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002210808,"gmtCreate":1642027149507,"gmtModify":1676533672032,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to buy more","listText":"Time to buy more","text":"Time to buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002210808","repostId":"1117693983","repostType":2,"repost":{"id":"1117693983","pubTimestamp":1641989077,"share":"https://www.laohu8.com/m/news/1117693983?lang=&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer&#39;s PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer  announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}